GW Pharmaceutical

GW Pharmaceuticals Stock Soaring and Spurring on Bullish Calls After Q1

GWPH Profile

  • Sector: Health Technology
  • Industry: Pharmaceuticals: Other
  • Employees: 901

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Recent News

JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results of the company’s positive Phase 3 clinical trial of […]

Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

– Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex – CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety of data, including long-term data in the treatment of tuberous sclerosis […]

Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

– Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis – Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed CARLSBAD, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Greenwich Biosciences, U.S. subsidiary of […]

Loading…

Something went wrong. Please refresh the page and/or try again.